Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics


Xenon Pharmaceuticals Inc. (XENE)

Today's Latest Price: $9.72 USD

0.10 (1.04%)

Updated Oct 30 4:00pm

Add XENE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

XENE Stock Summary

  • The ratio of debt to operating expenses for Xenon Pharmaceuticals Inc is higher than it is for about only 5.23% of US stocks.
  • With a year-over-year growth in debt of -94.42%, Xenon Pharmaceuticals Inc's debt growth rate surpasses merely 1.58% of about US stocks.
  • As for revenue growth, note that XENE's revenue has grown 299.63% over the past 12 months; that beats the revenue growth of 97.86% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Xenon Pharmaceuticals Inc are NXTC, VBLT, NTLA, FULC, and KALV.
  • XENE's SEC filings can be seen here. And to visit Xenon Pharmaceuticals Inc's official web site, go to www.xenon-pharma.com.

XENE Stock Price Chart Interactive Chart >

Price chart for XENE

XENE Price/Volume Stats

Current price $9.72 52-week high $18.45
Prev. close $9.62 52-week low $7.00
Day low $9.32 Volume 149,900
Day high $10.16 Avg. volume 201,932
50-day MA $11.20 Dividend yield N/A
200-day MA $12.54 Market Cap 340.15M

Xenon Pharmaceuticals Inc. (XENE) Company Bio


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.


XENE Latest News Stream


Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream


Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript

Xenon Pharmaceuticals, Inc. (XENE) Q2 2020 Earnings Conference Call August 06, 2020, 17:30 ET Company Participants Jodi Regts - VP, Corporate Affairs & IR Simon Pimstone - CEO & Director Ian Mortimer - President, CFO & Company Secretary Conference Call Participants Alex Thompson - Stifel Andrew Tsai - Jefferies Laura...

SA Transcripts on Seeking Alpha | August 9, 2020

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. …

GlobeNewswire | August 6, 2020

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today…

GlobeNewswire | July 30, 2020

Did Hedge Funds Make The Right Call On Xenon Pharmaceuticals Inc (XENE) ?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | July 12, 2020

Neurocrine Adds to Pipeline With $2 Billion Takeda Deal

Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...

Yahoo | June 17, 2020

Read More 'XENE' Stories Here

XENE Price Returns

1-mo -13.14%
3-mo -11.07%
6-mo -25.46%
1-year 11.60%
3-year 213.55%
5-year 14.62%
YTD -25.86%
2019 107.77%
2018 123.36%
2017 -63.31%
2016 -4.23%
2015 -59.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7677 seconds.